[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Zhongshan Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":592},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,219,0,25,[9,44,66,90,116,148,170,190,215,237,259,283,306,327,349,371,389,424,445,470,490,508,526,547,564],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100636140",false,"NCT07561814","A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed diagnosis of pancreatic cancer.\n* Availability of preoperative and postoperative contrast-enhanced CT images at the participating center; patient records include corresponding clinical data, postoperative pathological reports, and preoperative and postoperative blood test results.\n* Underwent surgical treatment for pancreatic cancer at a participating center of this study.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years (minors).\n* Presence of other severe diseases (e.g., severe liver or kidney failure, cardiovascular or cerebrovascular diseases, malignancies other than pancreatic cancer); pregnant or breastfeeding women; individuals with mental illness;\n* patients unable to comply with follow-up or provide informed consent.\n* Presence of significant outliers (e.g., laboratory values exceeding 10 times the normal range without clinically reasonable explanation) or samples with excessive missing data.","ALL","18 Years",{"count":18,"type":19},1030,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress.\n\nThe main questions it aims to answer are:\n\n* Can combining these types of data more accurately estimate how long a person might survive?\n* Can it better predict the risk of recurrence?\n\nParticipants will not have any extra tests or treatments. They will:\n\n* Allow researchers to collect information from their existing medical records (such as surgery reports, imaging, and lab results)\n* Receive a follow-up phone call for up to 3 years to share health updates（about every 3 months for the prospective cohort）.",[23],"Pancreatic Cancer",[25,26,27,28,29,30],"Pancreatic cancer","Multimodal data","Deep learning","Predictive model","Prognosis","CT imaging","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2025-12-09",{"date":39,"type":19},"2029-12-31",{"name":41,"class":42},"Shanghai Zhongshan Hospital","OTHER",1,{"id":45,"slug":4,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":43},"100644850","NCT07677410","Aspirin Monotherapy Versus Sequential Warfarin-Aspirin Therapy After TAVR in Patients With Pure Aortic Regurgitation","Prospective, Multicenter, Randomized Controlled Trial Evaluating the Safety and Efficacy of Different Antithrombotic Therapy Strategies in Patients With Severe Aortic Regurgitation Undergoing Transcatheter Aortic Valve Replacement","AWATAR","Inclusion Criteria:\n\n* Age ≥18 years.\n* Patients with severe aortic regurgitation (AR) who achieve technical success after TAVR using devices specifically indicated for AR (per VARC-3 criteria).\n* Trileaflet aortic valve anatomy.\n* No long-term anticoagulation indication (including but not limited to: atrial fibrillation, mechanical mitral valve prosthesis, deep vein thrombosis, pulmonary embolism, left ventricular thrombus, pulmonary hypertension, or coagulation disorders) as confirmed by the investigator.\n* Signed written informed consent and willingness to comply with randomization, study procedures, and follow-up.\n\nExclusion Criteria:\n\n* Need for oral anticoagulation or dual antiplatelet therapy, or need for oral or intravenous strong CYP3A inhibitors that cannot be paused during the study period.\n* Active pathological bleeding, subdural hematoma, or history of intracranial hemorrhage.\n* Ischemic stroke within 30 days before TAVR.\n* Acute myocardial infarction within 30 days.\n* Severe hepatic insufficiency (cirrhosis, hepatic decompensation).\n* Severe renal insufficiency (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or need for renal replacement therapy.\n* Stent implantation (including coronary, carotid, or peripheral arteries) within 12 months before TAVR, or planned stent implantation within 1 year after TAVR.\n* Coronary artery bypass grafting (CABG) within 12 months before TAVR.\n* Allergy, intolerance, or known resistance to aspirin, clopidogrel, or warfarin.\n* Known coagulation disorders or bleeding diathesis (including but not limited to platelet count ≤50,000\u002Fmm³ at screening).\n* Any contraindication to anticoagulation therapy.\n* Prior aortic valve prosthesis (mechanical or bioprosthetic); mitral valve bioprosthesis replacement within 1 year before TAVR; or prior mitral mechanical valve replacement; or prior tricuspid valve replacement.\n* Emergency TAVR with cardiogenic shock manifesting as low cardiac output, vasopressor or respiratory dependence, or mechanical hemodynamic support.\n* Life expectancy \\\u003C1 year (e.g., terminal malignancy).\n* Participation in another investigational drug or device clinical study (patients who have completed the primary endpoint of the study and are currently in long-term follow-up are not excluded).\n* Pregnancy or planned pregnancy, or use of estrogen or estrogen-like drugs (for women with suspected pregnancy, serum or urine human chorionic gonadotropin test must be negative before enrollment).\n* Any other condition deemed by the investigator to be inappropriate for study participation.",{"count":52,"type":19},1172,"INTERVENTIONAL",[55],"NA","This multicenter randomized controlled trial evaluates antithrombotic strategies post-TAVR in severe aortic regurgitation patients without long-term anticoagulation. Patients are randomized 1:1 to aspirin 75-100 mg daily for 12 months versus warfarin (INR 2-3) for 6 months followed by aspirin for 6 months. Primary hypothesis: aspirin is superior for bleeding and non-inferior for death\u002Fthrombosis. Primary endpoint is a composite of death, stroke, thrombosis, MI, embolism, and major bleeding at 1 year. Sample size: 1172. Follow-up: 30 days, 6 months, 12 months.",[58],"Aortic Regurgitation Disease","NOT_YET_RECRUITING","2026-06-29",{"date":32,"type":35},{"date":32,"type":19},{"date":64,"type":19},"2030-07-01",{"name":41,"class":42},{"id":67,"slug":4,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":53,"phases":74,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":43},"100645381","NCT07681232","EIT-Guided Visual Feedback During Incentive Spirometry for Postoperative Atelectasis","Effects of Electrical Impedance Tomography-Guided Visual Feedback During Incentive Spirometry on the Immediate Ventilation Distribution in Postoperative Patients With Atelectasis: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Admitted to an intensive care unit or postoperative monitoring unit after major thoracic or upper-abdominal surgery; tracheal tube removed; spontaneously breathing; and clinically stable.\n3. Alert and able to understand and follow incentive-spirometry and EIT instructions.\n4. Bedside lung ultrasound shows atelectasis or markedly reduced aeration in dorsal or posterolateral lung regions, with the lung-ultrasound assessment recorded.\n5. Baseline EIT during quiet breathing in a semi-recumbent position shows insufficient dorsal ventilation with potential for improvement; dorsal ventilation fraction below 50%.\n6. Written informed consent provided by the participant or legally authorized representative according to the ethics-approved process, with participant re-consent when decision-making capacity returns.\n\nExclusion Criteria:\n\n1. Ongoing invasive mechanical ventilation or noninvasive ventilation, or high-flow nasal oxygen when study conditions cannot be maintained stably.\n2. Hemodynamic instability or inability to tolerate a semi-recumbent position.\n3. Inability to cooperate with training or impaired consciousness.\n4. Unsuitable for EIT monitoring, including an implanted pacemaker or defibrillator incompatible with the device, severe skin disease at the electrode-belt site, or known relevant allergy.\n5. Severe underlying pulmonary disease likely to substantially affect ventilation distribution and obscure the intervention effect.\n6. Chest-wall deformity or severe scoliosis affecting EIT image quality.\n7. Body mass index greater than 35 kg\u002Fm2.\n8. Pregnancy or breastfeeding.\n9. Current participation in another interventional clinical trial that could interfere with study outcomes.\n10. Any other condition that, in the investigator's judgment, makes participation inappropriate.",{"count":73,"type":19},60,[55],"This single-center randomized controlled trial will evaluate whether real-time visual feedback from electrical impedance tomography (EIT) improves the immediate distribution of lung ventilation during incentive spirometry in adults with postoperative atelectasis. Approximately 60 participants will be randomized 1:1 to receive either EIT-guided visual feedback or standardized verbal guidance during one session of 30 incentive-spirometry breaths. The primary outcome is the change in dorsal ventilation fraction from before training to 5 minutes after training. Secondary outcomes include inspiratory capacity, ventilation homogeneity, dependent silent spaces, end-expiratory lung impedance, oxygenation, in-hospital intubation or reintubation, and intervention-related adverse events.",[77],"Postoperative Atelectasis",[79,80,81,82,83],"Electrical Impedance Tomography","Incentive Spirometry","Visual Feedback","Pulmonary Rehabilitation","Dorsal Ventilation","2026-06-26",{"date":34,"type":35},{"date":32,"type":19},{"date":88,"type":19},"2027-12-31",{"name":41,"class":42},{"id":91,"slug":4,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":43},"100644949","NCT07676864","Eye Tracking for Early Identification of Post-ICU Cognitive Impairment","Early Identification of Post-ICU Cognitive Impairment Using Eye-Tracking Technology: A Prospective Observational Study","Inclusion Criteria:\n\n* Successfully transferred from the ICU to a general ward after ICU treatment.\n* ICU length of stay of at least 24 hours.\n* Conscious and able to cooperate with cognitive assessment and eye-tracking tests.\n* Willing to participate in the study and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Diagnosed with cognitive impairment before ICU admission, such as Alzheimer's disease, based on medical history or previous medical records.\n* Previous diagnosis of mental illness or intellectual developmental disorder.\n* Severe visual, hearing, or eye disease that prevents completion of cognitive assessment or eye-tracking tasks.\n* Severe neurological disease that may affect cognitive function, such as stroke, traumatic brain injury, or intracranial infection.\n* Unable to understand or complete the cognitive assessment or eye-tracking tasks due to severe fatigue, marked inattention, communication disorder, or other reasons as assessed by the research staff.",true,{"count":98,"type":19},73,"Some patients may have problems with memory, attention, thinking speed, or other cognitive functions after leaving the intensive care unit (ICU). This is called post-ICU cognitive impairment. Early recognition of this problem may help clinicians provide follow-up care and support more promptly.\n\nThis study will explore whether eye-tracking technology can help identify cognitive impairment in patients soon after ICU discharge. Eye tracking is a non-invasive test that records eye movements while a person looks at images or completes simple visual tasks on a screen. The test does not involve any treatment or change in usual medical care.\n\nParticipants will be adult patients who have been transferred from the ICU to a general ward. Within 7 days after ICU discharge, participants will complete a cognitive assessment and an eye-tracking test. The study team will also collect relevant clinical information from medical records. Patients will be grouped according to whether they have post-ICU cognitive impairment based on cognitive assessment and clinical judgment.\n\nThe main purpose of this study is to assess whether information obtained from eye-tracking tests can help clinicians identify possible post-ICU cognitive impairment at an early stage, when used together with standard cognitive assessment. The study will also compare eye movement patterns between the two groups and explore whether eye-tracking measures add useful information beyond standard cognitive assessment.",[101,102],"Post Intensive Care Syndrome (PICS)","Cognitive Impairment",[104,102,105,106,107],"Eye Tracking","Cognitive Assessment","Intensive Care Unit","Post intensive Care Syndrome","2026-06-24",{"date":110,"type":35},"2026-06-30",{"date":112,"type":19},"2026-08",{"date":114,"type":19},"2027-05",{"name":41,"class":42},{"id":117,"slug":4,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":123,"targetDuration":125,"studyType":20,"phases":4,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},"100633664","NCT07529626","Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer","A Prospective Cohort Study on the Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer: A Comprehensive Analysis Based on Multidimensional Dynamic Psychological Assessment (MIND-PANC)","MIND-PANC","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed diagnosis of pancreatic cancer, or other pancreatic diseases.\n* Conscious, with basic reading\u002Fwriting or communication skills, able to understand and complete the questionnaire assessments (either independently, with assistance from research staff, or with help from a family member).\n* Voluntarily agree to participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Presence of severe cognitive impairment (e.g., dementia, disturbance of consciousness) or a definite history of psychiatric disorders, judged by the investigator as unable to comply with the study assessments, and without a family member who can help complete the questionnaire assessments.\n* Presence of other severe, uncontrolled systemic diseases (e.g., severe heart, lung, or kidney failure), with an estimated life expectancy \\\u003C 3 months as judged by the investigator.\n* Inability to understand Chinese or presence of severe visual\u002Fhearing impairment that affects completion of the questionnaire assessments, and without a family member who can help complete the questionnaire assessments.",{"count":124,"type":19},320,"3 Years","This is a prospective, observational cohort study (MIND-PANC) to explore the associations of chronic psychological stress with disease progression, treatment outcomes, and prognosis of pancreatic cancer.\n\nResearchers will ask participants to fill out simple questionnaires about their mood, worries, and sleep at the start of the study and at regular follow-up visits. The study will also collect a small blood sample (leftover from routine care) to measure stress-related markers.\n\nInvestigators hypothesize that pancreatic cancer patients who have higher levels of ongoing psychological stress (such as anxiety, depression, or poor sleep) tend to have shorter survival times, a higher chance of recurrence, and a poorer response to treatment, compared to patients with lower stress levels.",[128,129,130],"Pancreatic Tumor, Benign","Pancreatic Cancer, Adult","Pancreatic Cancer Resectable",[132,133,134,135,136,137,138,139,140],"pancreatic cancer","anxiety","depression","psychological distress","Hospital Anxiety and Depression Scale","Pittsburgh Sleep Quality Index","disease progression","Overall survival","quality of life",{"date":60,"type":35},{"date":143,"type":35},"2026-05-11",{"date":145,"type":19},"2028-12-31",{"name":41,"class":42},3,{"id":149,"slug":4,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":53,"phases":156,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100644625","NCT07671391","A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants","A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body Composition in Obese Participants","Inclusion Criteria:\n\n1. Voluntarily participate in the study and sign the Informed Consent Form (ICF);\n2. Male or female participants aged between 18 and 75 years (inclusive) at the time of signing the ICF;\n3. BMI ranging from 28.0 to 40.0 kg\u002Fm2 during the screening;\n4. Self-reporting at least one experience of weight loss failure after adjusting diet and exercise, and within the previous 3 months, the weight change after only dietary and exercise adjustments was less than 5%;\n\nExclusion Criteria:\n\n1. A clear diagnosis of type 1, type 2 diabetes or other types of diabetes (excluding gestational diabetes);\n2. Screening criteria: Glycated hemoglobin ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol\u002FL.\n\n   Obesity related:\n3. Diagnosed with secondary obesity;\n4. Previously underwent surgical or endoscopic weight loss metabolic surgery (except for local liposuction within 1 year before screening) or gastric balloon implantation, or planned to undergo any weight loss surgery or receive other weight loss treatments during the study;\n5. Uncontrolled thyroid disease, or screening criteria.","75 Years",{"count":73,"type":19},[157],"PHASE2","This study is a randomized, double-blind, placebo-controlled trial aimed at exploring the effects of LAE102 injection in combination with Tirzepatide on body composition.",[160],"Obesity Adult Onset",[162,160,163],"LAE102 injection","Investigator-initiated trial","2026-06-22",{"date":84,"type":35},{"date":112,"type":19},{"date":168,"type":19},"2027-12",{"name":41,"class":42},{"id":171,"slug":4,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":15,"minAge":176,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":53,"phases":179,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":187,"leadSponsor":189,"locationsCount":43},"100640190","NCT07621380","Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction","Effect of Ertugliflozin on NT-proBNP and Cardiac Function After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial","Inclusion Criteria:\n\n1. Adults aged 19 years or older\n2. Clinically confirmed type 2 diabetes mellitus (T2DM)\n3. First acute myocardial infarction (AMI) with planned randomization within 72 hours of AMI onset\n4. Ability to understand and voluntarily sign written informed consent\n\nExclusion Criteria:\n\n1. Type 1 diabetes mellitus or history of diabetic ketoacidosis\n2. Gestational diabetes, pregnancy, or breastfeeding\n3. End-stage renal disease (ESRD), dialysis, or prior kidney transplantation\n4. Use of any SGLT2 inhibitor within 4 weeks prior to enrollment\n5. Hemodynamic instability or investigator judgment that participation is not in the patient's best interest\n6. Systolic blood pressure \\\u003C 90 mmHg at enrollment or requiring vasopressors to maintain blood pressure","19 Years",{"count":178,"type":19},476,[180],"PHASE4","This prospective, randomized, open-label, blinded endpoint (PROBE) trial evaluates the efficacy of early ertugliflozin initiation (10 mg daily) compared to standard care alone on cardiac function in 476 adult patients with type 2 diabetes mellitus (T2DM) following a first acute myocardial infarction (AMI). The study is supported by scientific rationale suggesting potential effects of ertugliflozin on cardiac resident macrophages in the heart after myocardial infarction.The primary objective is to assess the change in NT-proBNP levels from baseline to 26 weeks, while secondary endpoints explore echocardiographic parameters (such as LVEF and LAVi) and metabolic indices including blood ketone levels, HbA1c, and body weight. Eligible participants are randomized in a 1:1 ratio within 72 hours of AMI onset and followed for a total of 30 weeks to monitor both efficacy outcomes and safety events, with a specific focus on serious adverse events like severe hypoglycemia, genital infections, and ketoacidosis.",[183],"Type 2 Diabetes Mellitus Myocardial Infarction","2026-06-21",{"date":108,"type":35},{"date":32,"type":19},{"date":188,"type":19},"2028-03-01",{"name":41,"class":42},{"id":191,"slug":4,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":214},"100644345","NCT07663253","Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients","A Single-Arm, Multicenter, Prospective, Observational Clinical Study on the Efficacy and Safety of Isatuximab Combined With Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Regimen in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TI-NDMM) Patients","CHAMPION-01","Inclusion Criteria:\n\n* Age ≥18 years\n* Newly diagnosed transplant-ineligible multiple myeloma patients as assessed by investigator, specifically referring to CSCO guidelines\n* Must meet corresponding laboratory test results (refer to restrictions in package inserts of combination drugs):\n\n  * Absolute neutrophil count (ANC) ≥1.0×10⁹\u002FL\n  * Platelet count ≥50×10⁹\u002FL\n  * Calculated creatinine clearance ≥30 mL\u002Fmin (using Cockcroft-Gault formula)\n  * Total bilirubin ≤3× upper limit of normal (ULN)\n* TI-NDMM patients intended for Isa-VRd regimen treatment as determined by investigator judgment, independent of study objectives Signed informed consent form (by patient or their legal representative)\n\nExclusion Criteria:\n\n* Patients currently participating in other interventional clinical studies\n* Patients with known severe hypersensitivity reactions to Isatuximab or any other excipients\n* Severe bacteremia at the time of administration\n* Currently uncontrolled cardiovascular disease, including:\n\n  * Uncontrolled hypertension\n  * Uncontrolled arrhythmia\n  * Uncontrollable congestive heart failure\n  * Unstable angina\n* Patients with peripheral neuropathy ≥Grade 2\n* Active infectious disease, known human immunodeficiency virus (HIV) positivity, active hepatitis B or hepatitis C\n* Patients who are currently pregnant\n* Patients who, at the physician's discretion, are unable to tolerate any drug in the combination regimen",{"count":198,"type":19},333,"Primary Objective of the trial is to evaluate the efficacy and safety of Isa-VRd-based regimen in transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) patients receiving treatment in real-world clinical practice in China.\n\nAnd Secondary Objectives is， To assess the MRD negativity rate in Chinese TI-NDMM patients treated with Isa-VRd To assess the safety and tolerability of Isa-VRd in Chinese TI-NDMM patients\n\nParticipants will:\n\nReceive Isatuximab 10 mg\u002Fkg iv\n\n* Cycle 1: Every weeks on Days 1, 8, 15, and 22\n* Cycles 2-8: Every 2 weeks on Days 1 and 15 Receive Bortezomib subcutaneous injection 1.3 mg\u002Fm²\n* Cycles 1-8: Days 1, 8, and 15 of each cycle Receive Lenalidomide oral 25 mg\u002Fday\n* Cycles 1-8: Days 1-21 at 25 mg\u002Fday (10 mg\u002Fday for patients with creatinine clearance \\[CrCl\\] ≥30 and \\\u003C60 mL\u002Fmin) Receive Dexamethasone oral 20 mg\n* Cycles 1-8: Days 1, 8, 15, and 22 of each cycle Following Cycle 8, the investigator may assess and adjust the treatment regimen During the induction phase, efficacy assessment is recommended at each treatment cycle. Patients who achieve ≥CR at the end of induction are recommended to undergo the first MRD monitoring assessment.\n\nDuring the maintenance phase, efficacy assessment is recommended at least every 3 cycles. Patients are recommended to undergo MRD status monitoring (≥CR) every 6 months (i.e., at months 14, 20, and 26) for MRD assessment.\n\nDuring the follow-up period, MRD status monitoring (≥CR) is recommended every 12 months to observe the depth of response.",[201],"Multiple Myeloma",[203,204,205,201],"isatuximab","transplant-ineligible newly diagnosed multiple myeloma","TI NDMM","2026-06-17",{"date":208,"type":35},"2026-06-23",{"date":210,"type":19},"2026-06",{"date":212,"type":19},"2030-09",{"name":41,"class":42},13,{"id":216,"slug":4,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":234,"leadSponsor":236,"locationsCount":4},"100641077","NCT07625735","MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastric Cancer","Mismatch Repair (MMR) Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastric Cancer","Inclusion Criteria:\n\n1. Upfront surgery cohort\n\n   * Patients who underwent radical surgery for gastric cancer at Zhongshan Hospital, Fudan University.\n   * Patients who did not receive neoadjuvant chemotherapy, radiotherapy, immunotherapy, or other antitumor treatments that may affect the pathological assessment of the primary tumor or lymph node metastasis before surgery.\n   * Patients with pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma after surgery, including Siewert type II and III tumors only.\n   * Patients with definite pathological assessment of lymphatic invasion and regional lymph node status.\n   * Patients with available and definite MMR status.\n2. ESD cohort\n\n   * Patients who underwent ESD for gastric cancer at Zhongshan Hospital, Fudan University.\n   * Patients with pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma after ESD, including Siewert type II and III tumors only.\n   * Patients with complete post-ESD pathological information, including histological type, depth of invasion, tumor size, ulcerative findings, lymphatic invasion status, venous invasion status, horizontal margin status, and vertical margin status.\n   * Patients with available and definite MMR status.\n\nExclusion Criteria:\n\n1. Upfront surgery cohort\n\n   * Patients with other pathological types, such as gastric squamous cell carcinoma or neuroendocrine carcinoma.\n   * Patients who received neoadjuvant treatment before surgery, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, or other systemic antitumor treatments.\n   * Patients with missing postoperative pathological information, resulting in inability to determine lymphatic invasion or regional lymph node metastasis status.\n   * Patients with missing or indeterminate MMR status.\n   * Patients with concurrent malignancies that may interfere with the determination of the origin of lymph node metastasis.\n2. ESD cohort\n\n   * Patients with other pathological types, such as gastric squamous cell carcinoma or neuroendocrine carcinoma.\n   * Patients with missing post-ESD pathological information that precludes eCURA classification, eCURA risk score calculation, or assessment of lymphatic invasion status.\n   * Patients with missing or indeterminate MMR status.","95 Years",{"count":223,"type":19},3000,"Brief Summary\n\nLymph node metastasis (LNM) is a key factor influencing treatment decisions and prognosis in patients with gastric cancer. Lymphatic invasion (LI) is an important pathological predictor of LNM and a core component of the eCURA risk scoring system after endoscopic submucosal dissection (ESD) for early gastric cancer. However, whether LI has the same predictive value for LNM across different mismatch repair (MMR) statuses remains unclear. Compared with proficient mismatch repair (pMMR) gastric cancer, deficient mismatch repair (dMMR) gastric cancer has distinct molecular pathological features and an immune-enriched tumor microenvironment. In early gastric cancer, if LI is associated with a lower LNM risk in dMMR tumors than in pMMR tumors, existing LI-based eCURA risk assessment may overestimate LNM risk in patients with dMMR early gastric cancer and consequently affect decisions regarding additional surgery after ESD. Therefore, this study aims to systematically evaluate the impact of MMR status on the association between LI and LNM using upfront-surgery and post-ESD additional-surgery cohorts from our center, and to explore the potential clinical value of MMR status in refining eCURA-based risk stratification for early gastric cancer.",[226,227,228,229],"Gastric \u002F Gastroesophageal Junction Adenocarcinoma","Mismatch Repair Deficient or MSI-High Solid Tumors","Lymph Node Metastasis","Lymphatic Invasion","2026-06-16",{"date":232,"type":35},"2026-06-18",{"date":32,"type":19},{"date":235,"type":19},"2027-07-31",{"name":41,"class":42},{"id":238,"slug":4,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":53,"phases":246,"briefSummary":247,"conditions":248,"keywords":251,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":43},"100641201","NCT07616024","Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Patients With ST-segment Elevation Myocardial Infarction","Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Primary percuTaneous Coronary Intervention for Patients With ST-segment Elevation Myocardial Infarction","INSIGHT-STEMI","Inclusion criteria\n\n1. Patients diagnosed with acute ST-segment elevation myocardial infarction (STEMI) who have an indication for emergency interventional therapy;\n2. Subjects who are eligible to undergo primary percutaneous coronary intervention (PCI);\n3. Subjects or their authorized family members voluntarily agree to participate in the clinical trial and sign the written informed consent form;\n4. The IVUS catheter is expected to pass through the target lesion to complete the examination.\n\nExclusion Criteria\n\n1. Patients with cardiogenic shock or severe heart failure (Killip class IV);\n2. Patients who have previously undergone coronary artery bypass grafting (CABG);\n3. Patients with coma or disturbance of consciousness;\n4. Patients who are expected to be intolerant to long-term antiplatelet therapy;\n5. Pregnant women;\n6. Life expectancy \\\u003C 1 year;\n7. Currently participating in another drug\u002Fdevice clinical trial and not having reached the primary endpoint;\n8. Poor compliance, expected to be unable to complete follow-up.",{"count":245,"type":19},2488,[55],"STEMI represents the subtype of ACS with the worst prognosis, associated with high mortality and an elevated risk of complications. The use of IVI guidance holds the potential to reduce the incidence of MACE. In previous studies, there has been limited research on intravascular imaging in the context of primary revascularization procedures for STEMI, and no large-scale cohort study has compared the differences in clinical outcomes between IVI-guided and angiography-guided primary revascularization. Therefore, we conducted this large-scale randomized controlled trial to compare IVI-guided primary PCI versus coronary angiography-guided primary PCI in patients with STEMI.",[249,250],"STEMI","PCI",[249,250,252],"IVUS",{"date":232,"type":35},{"date":255,"type":19},"2026-06-01",{"date":257,"type":19},"2032-12-31",{"name":41,"class":42},{"id":260,"slug":4,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":53,"phases":267,"briefSummary":269,"conditions":270,"keywords":273,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":43},"100635888","NCT07558538","A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome","Inclusion Criteria:\n\n1. Aged ≥18 years and \\\u003C80 years, male or female.\n2. Definite diagnosis of acute respiratory distress syndrome (ARDS) according to the Berlin Definition.\n3. Patients with PaO₂\u002FFiO₂ \\\u003C 200 mmHg and receiving invasive mechanical ventilation via endotracheal intubation.\n4. Diagnosis of ARDS confirmed no more than 72 hours prior to enrollment.\n5. No plan for parenthood within 1 year and agree to take effective contraceptive measures during the study period. Female participants of childbearing potential must have a negative serum pregnancy test.\n6. The subject fully understands the purpose of the study, as well as the nature, methods, and potential reactions of the investigational drug. The subject voluntarily signs the informed consent form to participate in the study and agrees to comply with the requirements of the study protocol. If the subject is unable to provide consent or has limited capacity to consent, consent must be obtained from the subject's legal guardian.\n\n   \\-\n\nExclusion Criteria:\n\n1. Use of inhaled pulmonary vasodilators (e.g., nitric oxide or prostaglandins).\n2. Current receipt or planned receipt of extracorporeal membrane oxygenation (ECMO) during the study period.\n3. Expected survival \\\u003C 3 months due to causes other than respiratory failure.\n4. Cerebrovascular or cardiovascular events within 3 months prior to study drug administration, including unstable angina, congestive heart failure, myocardial infarction within the past 12 months, hemodynamic instability, known left ventricular ejection fraction (LVEF) \\\u003C 40%, or clinically significant arrhythmia or conduction abnormality.\n5. Inability to tolerate single-use bronchoscopic imaging catheter examination, including but not limited to the following: active massive hemoptysis; severe hypertension and arrhythmia; myocardial infarction or unstable angina within 4-6 weeks prior to screening; severe cardiac dysfunction; uncorrectable bleeding tendency (platelet count \\\u003C 60 × 10⁹\u002FL), such as severe coagulation disorders, uremia, or severe pulmonary hypertension; severe superior vena cava syndrome; suspected aortic aneurysm; multiple pulmonary bullae.\n6. History of severe allergic reaction, or known allergy or hypersensitivity to any component of the investigational product.\n7. Breastfeeding or pregnant women.\n8. Participation in any drug clinical trial within 3 months prior to enrollment.\n9. Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.","80 Years",{"count":266,"type":19},24,[268],"EARLY_PHASE1","This study is a randomized, blank-controlled, open-label, single-dose, dose-escalation clinical study of rhKGF-2 in patients with ARDS.\n\nThe trial is designed with three dose groups (5 mg, 10 mg, and 15 mg), which will be escalated sequentially from the lowest dose group to the highest dose group. Each dose group will enroll 8 subjects, randomized in a 6:2 ratio according to the order of enrollment, to receive either the corresponding dose of rhKGF-2 (6 subjects) or serve as a blank control (2 subjects). Each subject will receive a single dose, administered once via a disposable bronchoscopic catheter.\n\nAll subjects will receive the trial intervention on top of standard ARDS treatment (see Concomitant Medications for details). Following the completion of drug administration, subjects will enter a 28-day follow-up period. Outcome measures include adverse events (AE), vital signs, laboratory parameters, oxygenation index (PFR), chest imaging changes, etc., to evaluate the safety, tolerability, and efficacy of the treatment.",[271,272],"ARDS (Moderate or Severe)","ARDS (Acute Respiratory Distress Syndrome)",[272,274],"rh-KGF2","2026-06-09",{"date":277,"type":35},"2026-06-11",{"date":279,"type":35},"2026-05-14",{"date":281,"type":19},"2026-12-30",{"name":41,"class":42},{"id":284,"slug":4,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":154,"enrollmentInfo":289,"targetDuration":4,"studyType":53,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":4},"100642842","NCT07644208","PD-1\u002FIL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy","A Phase II Study to Evaluate the Efficacy and Safety of PD-1\u002FIL-2 Bispecific Antibody as Neoadjuvant Therapy in Hepatocellular Carcinoma Patients With Early Recurrence After Curative Hepatectomy and Eligible for Re-resection","Inclusion criteria:\n\n1. Have signed the written informed consent form and be able to comply with all scheduled visits and study procedures specified in the protocol.\n2. Aged between 18 and 75 years old (inclusive), with no restriction on gender.\n3. Diagnosed with hepatocellular carcinoma (HCC) confirmed by histopathology or cytology, or meeting the clinical diagnostic criteria for HCC formulated by the American Association for the Study of Liver Diseases (AASLD) or the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer.\n4. Must provide tumor tissue specimens obtained from the initial surgical resection during the screening period.\n5. Have a history of curative hepatectomy for HCC, with pathologically confirmed tumor recurrence occurring 3 months to 2 years after surgery. Candidates shall be assessed by a multidisciplinary team (MDT) and meet all the following criteria for repeat resection:\n\n   CNLC stage Ia-Ib or IIa-IIb, with recurrent lesions confined to one hepatic lobe; Adequate liver function reserve with Child-Pugh Class A; The volume of the future liver remnant (FLR) accounts for ≥40% of the standard liver volume (SLV) in patients with chronic liver disease, liver parenchymal damage or liver cirrhosis, or ≥30% in patients without liver fibrosis or cirrhosis; No vascular tumor thrombus; No extrahepatic metastasis.\n6. Have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), and the lesion has not received any local therapy.\n7. Have adequate organ and bone marrow function. Laboratory test results obtained within 7 days prior to enrollment shall meet the following requirements. No blood products, erythropoietin, colony-stimulating factors, thrombopoietin, albumin or other parenteral corrective medications are allowed within 14 days before laboratory testing:\n\n   Hematology: Hemoglobin (HGB) ≥ 90 g\u002FL; Absolute Neutrophil Count (ANC) ≥ 1.5×10⁹\u002FL; Platelet (PLT) count ≥ 100×10⁹\u002FL.\n\n   Liver function: Total Bilirubin (TBIL) ≤ 1.5 × Upper Limit of Normal (ULN). Participants with TBIL \\> 1.5 × ULN but conjugated bilirubin ≤ ULN are also eligible; Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 5 × ULN; Alkaline Phosphatase (ALP) ≤ 4 × ULN; Serum albumin ≥ 30 g\u002FL.\n\n   Renal function: Serum Creatinine (Cr) ≤ 1.5 × ULN, or Creatinine Clearance (CCr) ≥ 50 mL\u002Fmin (calculated by the Cockcroft-Gault formula using actual body weight). Urinalysis shows urine protein \\\u003C 2+. For participants with urine protein ≥ 2+ at baseline, the 24-hour urinary protein quantification shall be \\\u003C 1 g.\n\n   Coagulation function: International Normalized Ratio (INR) ≤ 1.5 × ULN; Partial Thromboplastin Time (PTT) \u002F Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN. Participants on stable-dose anticoagulant therapy shall remain within the expected therapeutic range of the prescribed anticoagulants.\n8. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n9. Expected survival time of no less than 6 months.\n10. Female participants of childbearing potential and male participants whose partners are of childbearing potential must agree to use effective contraception throughout the treatment period and for 6 months after the last study drug administration.\n\nExclusion criteria:\n\n1. Histologically or cytologically confirmed diagnosis of tumors containing components such as fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, mixed carcinoma, and intrahepatic cholangiocarcinoma.\n2. Prior treatment with anti-PD-1\u002FPD-L1 agents or other antitumor immunotherapies.\n3. Presence of unresolved Grade \\>1 toxicities related to any previous antitumor therapy (persistent Grade 2 alopecia, anemia, peripheral neuropathy, electrolyte abnormalities manageable with treatment, and endocrine disorders well-controlled with hormone replacement therapy are excluded).\n4. History of hepatic encephalopathy or seizures; presence of active, newly diagnosed or untreated central nervous system metastases, spinal cord compression, carcinomatous meningitis or leptomeningeal metastases.\n5. Presence of clinically significant cardiovascular and cerebrovascular diseases, including:\n\n   * Severe conduction disorders (e.g., third-degree atrioventricular block);\n   * Symptomatic, clinically unstable arrhythmias or arrhythmias requiring clinical intervention;\n   * Corrected QT interval (QTc, calculated via Fridericia's formula) ≥ 480 ms;\n   * Uncontrolled hypertension (systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>90 mmHg despite optimal medical treatment), or history of hypertensive crisis or hypertensive encephalopathy;\n   * History of myocarditis;\n   * Symptomatic congestive heart failure (New York Heart Association Class II-IV) or left ventricular ejection fraction (LVEF) \\\u003C 50% on cardiac ultrasonography;\n   * Any arterial thrombosis, embolism or ischemic event within 6 months prior to the first study drug administration, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack;\n   * History of deep vein thrombosis, pulmonary embolism or other severe thromboembolic events within 6 months before enrollment (Thrombosis related to implantable venous access ports, catheters or superficial phlebitis is not defined as severe thromboembolism). Patients with adequately treated deep vein thrombosis may be enrolled if deemed stable by the investigator.\n6. Current or prior history of interstitial pneumonia, pulmonary fibrosis, pneumoconiosis, drug-induced pneumonitis, radiation pneumonitis, severe pulmonary dysfunction or other restrictive lung diseases requiring corticosteroids or other treatments.\n7. History of severe or uncontrolled allergic diathesis, drug allergy, asthma or atopic dermatitis.\n8. Known allergy to IL-2, sintilimab, other monoclonal antibodies or their excipients.\n9. Symptomatic pleural effusion, ascites or pericardial effusion requiring repeated drainage (Patients with effusions not requiring drainage or with no obvious reaccumulation within 3 days after drainage discontinuation are eligible for enrollment).\n10. History of active autoimmune diseases requiring systemic therapy (e.g., disease-modifying drugs, corticosteroids or immunosuppressants) within 2 years prior to the first drug administration. Replacement therapies (e.g., levothyroxine, insulin, physiological corticosteroids for adrenal or pituitary insufficiency) are not regarded as systemic treatment.\n11. History of allogeneic organ transplantation (including liver transplantation) or allogeneic hematopoietic stem cell transplantation.\n12. Active uncontrolled bleeding, known bleeding diathesis, unhealed severe wounds, ulcers or fractures; history of esophagogastric variceal bleeding caused by portal hypertension within the preceding 6 months. Grade 3 varices confirmed by endoscopy within 3 months before the first administration. Patients with evidence of portal hypertension (including splenomegaly on imaging) with high bleeding risk assessed by investigators shall undergo endoscopic evaluation.\n13. Presence of major gastrointestinal diseases within 6 months prior to or at the time of drug administration, including gastrointestinal perforation, severe gastrointestinal fistula (with severely impaired gastrointestinal function or requiring invasive intervention), history of intestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection complicated with chronic diarrhea), Crohn's disease, ulcerative colitis or long-standing chronic diarrhea.\n14. Confirmed HIV positivity or history of acquired immunodeficiency syndrome (AIDS); active hepatitis B or hepatitis C (HCV), or history of infection with the above viruses.\n\n    * For patients positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb), HBV DNA testing is required. Those with HBV DNA ≤ 10⁴ copies\u002FmL, ≤ 2000 IU\u002FmL or below the lower limit of quantification are eligible. HBsAg-positive patients must receive antiviral therapy throughout the study with regular HBV DNA monitoring.\n    * Patients with positive HCV serology but undetectable HCV RNA are permitted to enroll.\n    * Patients who have completed anti-HCV treatment with undetectable viral load are eligible for enrollment.\n15. Active tuberculosis, patients currently receiving anti-tuberculosis treatment or those who received anti-tuberculosis therapy within 1 year before the first drug administration; patients with active syphilis requiring treatment.\n16. Severe, active or uncontrolled infections, infections requiring intravenous systemic antibiotics, or unexplained fever (\\>38 °C) within 2 weeks prior to the first study drug administration.\n17. Diagnosis of other pathologically confirmed malignant tumors within 5 years before enrollment. Exceptions include radically cured basal cell carcinoma, squamous cell carcinoma of the skin, completely resected carcinoma in situ, radically resected local prostate cancer and papillary thyroid carcinoma, as well as other malignancies with complete remission, no evidence of active disease for at least 2 years prior to enrollment and extremely low recurrence risk.\n18. Excluded medications and treatments (None of the following interventions are allowed):\n\n    a Last dose of antitumor therapies administered within 4 weeks before the first study drug: systemic chemotherapy (2-week washout period for oral fluoropyrimidines), endocrine therapy, targeted therapy (washout period of 2 weeks or 5 half-lives, whichever is longer), immunotherapy and tumor embolization. Traditional Chinese medicines for antitumor indications or immunomodulatory drugs (e.g., thymosin, interferon, interleukin) last administered within 1 week prior to the first dose.\n\n    b. Participation in any medical device or other interventional clinical trials within 2 weeks before the first dose or during the study period.\n\n    c. Palliative radiotherapy administered within 2 weeks before the first dose. d. Live vaccines for infectious disease prophylaxis administered within 4 weeks before the first dose.\n\n    e. Immunosuppressants or systemic corticosteroids (equivalent to \\>10 mg prednisone per day) administered within 2 weeks before the first dose.\n\n    f. Major surgery performed within 4 weeks before the first dose.\n19. Pregnant or breastfeeding females, or females planning to become pregnant before drug administration, during treatment or within 6 months after the last dose of study drug.\n20. Any concomitant disease, prior treatment, abnormal laboratory findings, history of substance abuse or current substance use, which in the investigator's judgment may compromise patient safety, hinder informed consent acquisition, affect treatment compliance or interfere with the safety assessment of the study drug.",{"count":290,"type":19},30,[157],"This is a single-arm, phase II clinical study designed to evaluate the efficacy and safety of a recombinant PD-1\u002FIL-2 bispecific antibody, as neoadjuvant therapy in hepatocellular carcinoma (HCC) patients who experienced early recurrence after curative hepatectomy and were suitable for repeat surgical resection.\n\nA total of approximately 30 eligible participants are planned to be enrolled. All patients will receive neoadjuvant treatment with PD-1\u002FIL-2 bispecific antibody for 3 cycles. Curative re-resection will be performed 2 to 7 weeks after the last dose of PD-1\u002FIL-2 bispecific antibody for patients with resectable lesions confirmed by imaging assessment. Tumor evaluation will be conducted per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) throughout the study. Postoperative pathological assessment and long-term follow-up will be implemented after surgery.\n\nThe primary endpoint is the major pathological response (MPR) rate. Secondary endpoints include complete pathological response (pCR) rate, event-free survival (EFS), overall survival (OS), R0 resection rate, objective response rate (ORR), disease control rate (DCR), and the safety and tolerability profile . Exploratory endpoints aim to analyze the correlation between biomarkers (e.g., PD-L1 expression, tumor microenvironment) and treatment efficacy.\n\nThis study intends to explore the clinical value of PD-1\u002FIL-2 bispecific antibody in the neoadjuvant setting for recurrent resectable HCC, and provide evidence for its clinical application in this patient population.",[294],"Hepatocellular Carcinoma (HCC)",[296,297],"Hepatocellular Carcinoma","Neoadjuvant Therapy","2026-06-08",{"date":300,"type":35},"2026-06-12",{"date":302,"type":19},"2026-06-15",{"date":304,"type":19},"2029-04-01",{"name":41,"class":42},{"id":307,"slug":4,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":96,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":53,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":326},"100643363","NCT07634861","Evaluating a Text-Prompt AI Assistant for Chest CT Scans (AI-REPORT Study)","An Evaluation Study of a Text-Based Chest CT-Assisted Diagnostic System: A Two-stage, Multicenter, Multireader Multicase (MRMC), Self-Crossover Controlled Trial","AI-REPORT","Inclusion Criteria:\n\n* Active board certification and ongoing routine clinical practice as an attending radiologist\n* Independent institutional authority for chest CT image interpretation and final official diagnostic report issuance\n* A minimum of three years of post-certification clinical experience in specialized thoracic imaging\n* Legal and cognitive competence for study participation, with voluntary provision of written informed consent after full understanding of study purpose, procedures, risks and benefits\n\nExclusion Criteria:\n\n* Direct participation in the development, training or validation of the trial's evaluated AI system\n* Ongoing participation in concurrent studies with potential risks of interpretation bias, cognitive fatigue or study procedure interference (investigator-assessed)\n* Any actual or perceived conflict of interest related to the evaluated AI system or its developers that may compromise objectivity in image interpretation and diagnostic reporting",{"count":314,"type":19},100,[55],"This study aims to find out if an artificial intelligence (AI) system can help experienced radiologists write chest CT scan reports more quickly without lowering the quality of the report. Chest CT scans are common, and writing reports for them is a major part of a radiologist's job. In this trial, board-certified radiologists will interpret complex chest CT cases. For some cases, they will start with a complete draft report generated by the AI system, which they can review and edit as needed. For other cases, they will write the report from scratch without any AI help, following their usual routine. The main things we are measuring are: 1) how much time the AI draft saves, and 2) whether the final reports created with AI help are as good as or better than those written without it, as judged by other senior doctors who do not know which report came from which method. The hope is that this AI tool can make radiologists' work more efficient while maintaining high standards for patient care.",[318],"Thoracic Diseases","2026-06-07",{"date":275,"type":35},{"date":322,"type":19},"2026-06-20",{"date":324,"type":19},"2027-02-15",{"name":41,"class":42},2,{"id":328,"slug":4,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":346,"leadSponsor":348,"locationsCount":326},"100643559","NCT07640906","AI-Assisted Chest-CT Reporting for Enhanced Speed and Quality (The DOUBLE-ACE Study)","A Multicenter Comparative Study Evaluating the Impact of an AI-Assisted Chest CT Reporting System on Real-world Radiologist Performance: The DOUBLE-ACE Study","DOUBLE-ACE","The study participants include both the radiologists whose performance is evaluated and the chest CT scans they interpret. Eligibility criteria are defined for both.\n\n1\\. Inclusion Criteria\n\n1.1 For Radiologists\n\n1. Board-certified radiologists specializing in or routinely performing thoracic imaging.\n2. Employed at one of the participating study centers for the entire duration of both the without-AI and with-AI study periods.\n3. Interpreted a minimum of eligible chest CT scans (e.g., \\> 50 scans) during both the without-AI and with-AI data collection periods.\n\n1.2 For Chest CT Scans\n\n1. Non-contrast chest CT examinations performed for any clinical indication.\n2. Scans completed and finalized during the defined with-AI or without-AI study periods.\n3. Patient age 18 years or older at the time of the scan.\n\n2\\. Exclusion Criteria\n\n2.1 For Radiologists:\n\n1. Radiologists who joined, left, or were on extended leave (e.g., \\>4 weeks) from the participating center between the with-AI and without-AI study periods.\n2. Radiologists who interpreted fewer than the minimum required number of eligible scans in either study period.\n3. Radiologists who voluntarily decline to have their de-identified performance data included in the study analysis.\n4. Radiologists who decline to provide demographic or occupational information (e.g., years of professional experience or sex)-variables that may serve as potential confounders-will be excluded from adjusted and stratified analyses that require such covariates.\n\n2.2 For Chest CT Scans\n\n1. CT scans of pediatric patients (age \\\u003C 18 years).\n2. Contrast-enhanced chest CT studies.\n3. Studies performed for specific procedural guidance (e.g., biopsy, ablation).\n4. Studies deemed technically inadequate for primary interpretation by radiologist (e.g., severe motion artifact, incomplete study).\n5. Studies for which the AI system fails to generate a valid preliminary report draft. This includes possible system failures, algorithm errors, or cases where the generated draft is deemed technically unusable (e.g., empty, garbled, or based on critically flawed image analysis).\n6. The lack of relevant information (diagnosis, clinical scenario, etc.). Chest CT data will be excluded from corresponding analyses if the required information, which is necessary for confounding control, subgroup analyses, or other pre-specified analyses, is unavailable. Such scenarios include data that cannot be retrospectively retrieved, incompletely recorded, or restricted due to ethical or institutional requirements.",{"count":335,"type":19},75,"The goal of this observational study is to learn if an AI assistant tool can help doctors who read chest CT scans (called radiologists) write their reports faster and just as well or better. Chest CT scans are common pictures taken of the inside of the chest to help with diagnosis. The main questions the study aims to answer are: (1) Does using the AI tool save radiologists time when writing their reports? (2) Are the final reports written with the AI tool's help as good as or better than reports written without it? To answer these questions, researchers will compare two time periods at several hospitals. They will look at how long it took to write reports and how good the reports were, both from a time before the AI tool was available and from a time after it was in regular use. In this study, radiologists will use the AI tool as part of their normal daily work. The tool is built into the computer system they already use to look at scans. Researchers will then measure the time and quality of the reports produced during their regular shifts.",[318,338,339],"Chest CT Scan","Artificial Intelligence (AI) in Diagnosis",[341,342],"Chest CT scan","artificial intelligence","2026-06-05",{"date":277,"type":35},{"date":210,"type":19},{"date":347,"type":19},"2026-12",{"name":41,"class":42},{"id":350,"slug":4,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":53,"phases":356,"briefSummary":357,"conditions":358,"keywords":360,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":43},"100643534","NCT07638683","A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).","A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL)","Inclusion Criteria:\n\n1. Age ≥18 years, any sex\u002Fgender\n2. Diagnosis of multiple myeloma according to IMWG criteria\n3. Histopathologic diagnosis of AL amyloidosis confirmed by:\n\n   * Green birefringence under polarized light microscopy with Congo red staining; AND at least one of the following:\n\n     1. Immunohistochemistry and\u002For immunofluorescence\n     2. Mass spectrometry\n     3. Electron microscopy\u002Fimmunoelectron microscopy\n4. Measurable disease at screening\n5. Newly diagnosed, no prior anti-plasma cell therapy\n6. Adequate laboratory values:\n\n   * Hemoglobin ≥7.5 g\u002FdL\n   * Absolute neutrophil count ≥1.0×10⁹\u002FL\n   * Platelet count ≥70×10⁹\u002FL (platelet transfusion acceptable; \\>50×10⁹\u002FL if ≥50% bone marrow nucleated cells are plasma cells)\n   * ALT ≤2.5× upper limit of normal (ULN)\n   * AST ≤2.5× ULN\n   * Total bilirubin ≤2.0× ULN\n   * Creatinine clearance ≥30 mL\u002Fmin\n   * Corrected serum calcium ≤14 mg\u002FdL\n7. Male and female participants of childbearing potential must use at least 2 effective contraceptive methods during the study\n8. Voluntarily signed informed consent form (ICF)\n\nExclusion Criteria:\n\n1. Prior anti-myeloma therapy or stem cell transplantation\n2. Diagnosis of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma, primary AL amyloidosis without concurrent MM, Waldenström macroglobulinemia, plasma cell leukemia, POEMS syndrome, or other malignancies within 3 years prior to enrollment\n3. Active infection or autoimmune disease\n4. Uncontrolled diabetes, hypertension, or other comorbidities\n5. Pregnant or lactating female\n6. Currently participating in another interventional study\n7. Any other condition that the investigator considers unsuitable for study participation",{"count":290,"type":19},[157],"The goal of this clinical trial is to learn if teclistamab in combination with daratumumab (Tec-Dara) works to treat newly diagnosed multiple myeloma with concurrent light chain amyloidosis (MM+AL). It will also learn about the safety of this combination. The main questions it aims to answer are:\n\nDoes Tec-Dara improve the 1-year progression-free survival rate compared to historical data (50% to 75%) in MM+AL patients? What are the rates of hematologic response (ORR, VGPR, CR, MRD negativity) and organ response in MM+AL patients treated with Tec-Dara? What medical problems do participants have when taking Tec-Dara?\n\nParticipants will:\n\nReceive teclistamab subcutaneous injection with step-up dosing (0.06, 0.3, 1.5 mg\u002Fkg), followed by 1.5 mg\u002Fkg weekly in Cycle 1, 3.0 mg\u002Fkg every 2 weeks in Cycles 2-3, and 3.0 mg\u002Fkg every 4 weeks in Cycles 4-24 Receive daratumumab subcutaneous injection 1800 mg weekly in Cycles 1-2, every 2 weeks in Cycles 3-6, and every 4 weeks in Cycles 7-24 Continue treatment until disease progression, unacceptable toxicity, or a maximum of 24 cycles Undergo disease assessments every 28 days (±7 days) including laboratory tests for hematologic and organ response evaluation Provide bone marrow samples for MRD and RNA sequencing analysis",[201,359],"AL Amyloidosis",[201,359,361,362],"Teclistamab","Daratumumab","2026-06-04",{"date":365,"type":35},"2026-06-10",{"date":367,"type":19},"2026-05-22",{"date":369,"type":19},"2028-12-30",{"name":41,"class":42},{"id":372,"slug":4,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":53,"phases":380,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":386,"leadSponsor":388,"locationsCount":43},"100632074","NCT07508956","Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment","Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Open-Label, Randomized, Multi-Centered Phase III Trial","MRD-ATLAS-III","Inclusion Criteria:\n\n1. Able to provide written informed consent (ICF) and capable of understanding and agreeing to comply with the study requirements and assessment schedule;\n2. Male or female aged ≥ 18 years;\n3. Histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, with clinical TNM stage (according to the 8th edition of the AJCC\u002FUICC clinical TNM staging system for gastric cancer; see Appendix 1) of cIIB-IVA, and the primary gastric tumor assessed as amenable to radical resection;\n4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (see Appendix 2), fit to undergo surgical treatment with no contraindications to surgery;\n5. Capable of providing adequate tumor tissue obtained via gastroscopy (or other means) prior to neoadjuvant treatment for whole-exome sequencing;\n6. Females of childbearing potential must have a negative pregnancy test within 7 days before initiation of neoadjuvant treatment. Males and females of childbearing potential must agree to use adequate contraception during the study period and for 24 months after the last dose of study treatment (see Appendix 3);\n7. Hematologic and biochemical parameters meeting the following criteria prior to neoadjuvant treatment:\n\n   * Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL\n   * Platelet count (PLT) ≥ 75 × 10⁹\u002FL\n   * Hemoglobin (Hb) ≥ 80 g\u002FL\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN)\n   * Serum creatinine (Cr) ≤ 1.5 × ULN or estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin\u002F1.73 m²\n   * Serum albumin (ALB) ≥ 30 g\u002FL\n   * For subjects not receiving anticoagulant therapy: international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN, and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN; for subjects receiving anticoagulant therapy: PT within the expected therapeutic range for the anticoagulant;\n8. No prior anticancer therapy for the current study-related tumor prior to initiation of neoadjuvant treatment.\n\nExclusion Criteria:\n\n1. Patients deemed by the investigator to have significant contraindications to or intolerance of neoadjuvant\u002Fadjuvant therapy;\n2. Female patients of childbearing potential who have not undergone surgical sterilization or are not using adequate contraceptive measures, pregnant or lactating women, or male patients planning to father a child within a short period;\n3. Any severe or uncontrolled systemic disease, including but not limited to uncontrolled hypertension, active hemorrhage, diabetes mellitus, etc.;\n4. Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral therapy, including tuberculosis, human immunodeficiency virus (HIV) infection, etc.;\n5. Prior history of malignancy or current presence of another malignancy, except for completely resected basal cell or squamous cell skin cancer, superficial bladder cancer, or in situ carcinoma of the prostate, cervix, or breast with at least 5 years without recurrence;\n6. Other conditions deemed by the investigator to render the patient unsuitable for study participation.",{"count":379,"type":19},304,[381],"PHASE3","For locally advanced gastric adenocarcinoma\u002Fesophagogastric junction adenocarcinoma, the currently recommended treatment strategy per clinical guidelines is radical gastrectomy combined with perioperative therapy (including chemotherapy, immunotherapy, etc.). This approach involves several cycles of neoadjuvant therapy prior to surgery, followed by the surgical procedure, and then several cycles of adjuvant therapy post-surgery. This regimen is generally considered to offer favorable efficacy, ultimately leading to improved survival outcomes for patients. However, some patients are unable to complete the prescribed postoperative adjuvant therapy due to factors such as poor physical condition after surgery or cumulative treatment toxicity. Findings from the retrospective SPACE-FLOT study preliminarily suggest that for patients with a favorable response to neoadjuvant therapy, postoperative adjuvant therapy may not confer additional survival benefit, while potentially increasing the risk of treatment-related adverse events. Therefore, the investigators aim to utilize the latest technological approaches to identify patients who could safely forgo adjuvant therapy, enabling personalized treatment decisions, reducing unnecessary treatment, and thereby maximizing patients' long-term survival benefits.\n\nTo achieve this objective, the investigators have identified circulating tumor DNA (ctDNA) testing as a potential solution. ctDNA refers to DNA fragments released by tumor cells into the extracellular space (e.g., into the bloodstream). By drawing a small amount of peripheral blood and analyzing the ctDNA within, it is possible to detect minimal residual disease (MRD) that is difficult to identify through conventional imaging methods (such as CT or MRI) after treatment. MRD is considered a critical factor that may lead to tumor recurrence. Utilizing ctDNA to detect MRD enables a convenient and accurate assessment of tumor status and treatment efficacy, thereby offering the potential for personalized treatment.\n\nColorectal cancer represents a cancer type where ctDNA testing has been applied early and is relatively mature. In the field of colorectal cancer, the GALAXY study confirmed that ctDNA positivity can effectively predict patient survival outcomes, with superior performance to other traditional indicators. The study also found that patients with postoperative ctDNA MRD positivity tended to benefit from postoperative adjuvant chemotherapy, whereas those with ctDNA MRD negativity often did not derive such benefit. Subsequently, another randomized controlled trial (the DYNAMIC study) revealed that using ctDNA MRD to guide postoperative adjuvant chemotherapy strategies could effectively reduce unnecessary chemotherapy without adversely impacting patient survival outcomes.\n\nIn the field of gastric cancer, studies such as MENCA-GC, CRITICS, and PLAGAST have all demonstrated that postoperative ctDNA can effectively predict patient prognosis in the treatment model of radical gastrectomy combined with perioperative therapy. Additionally, preliminary findings from the ongoing MRD-GATE study indicate that in treatment models without preoperative neoadjuvant therapy (i.e., surgery followed by adjuvant therapy), utilizing ctDNA MRD to guide postoperative adjuvant treatment can also reduce unnecessary chemotherapy without compromising patient survival outcomes.\n\nThis study focuses on patients with locally advanced gastric cancer, integrating the latest clinical research advancements, and aims to fill the research gap concerning the efficacy of using ctDNA MRD to guide adjuvant therapy within the context of radical gastrectomy combined with perioperative therapy. This holds significant importance for optimizing treatment strategies and maximizing patient benefits.",[226],{"date":298,"type":35},{"date":255,"type":19},{"date":387,"type":19},"2032-03-31",{"name":41,"class":42},{"id":390,"slug":4,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":53,"phases":397,"briefSummary":399,"conditions":400,"keywords":406,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":43},"100639462","NCT07614061","Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer","A Phase I, Open-label Study to Evaluate the Safety and Efficacy of CD160-enhanced Autologous BTC-Ag-T Cells in Advanced Biliary Tract Malignancies","Major Inclusion Criteria:\n\nSubjects must meet all of the following criteria to be enrolled:\n\n1\\. Age\n\n\\- Age ≥ 18 years at the time of signing informed consent. 2. Diagnosis\n\n* Histologically or cytologically confirmed biliary tract malignancy (intrahepatic, perihilar, or distal extrahepatic cholangiocarcinoma, or gallbladder cancer).\n\n  3\\. Disease status\n* Locally advanced unresectable or metastatic disease 4. Prior systemic therapy\n* Patients (including those with refractory BTC and those with postoperative recurrence) must have received prior gemcitabine-based chemotherapy in combination with a PD-1\u002FPD-L1 inhibitor.\n\n  5\\. Measurable disease\n* At least one measurable lesion per RECIST v1.1 at baseline imaging.\n* Sufficient viable tumor tissue from biopsy for antigen-presenting tumor cell (APTC) manufacturing 6. Adequate venous access and overall condition to tolerate leukapheresis. 7. Washout and lymphocyte recovery before leukapheresis 8. ECOG performance status 0 or 1 9. Organ function\n* Hematology (no growth-factor support or transfusion within 5 days of testing, unless otherwise stated): ANC ≥ 1.0 × 10⁹\u002FL; platelets ≥ 75 × 10⁹\u002FL; hemoglobin ≥ 8.0 g\u002FdL (transfusion to reach this threshold is permitted).\n* Hepatic: total bilirubin ≤ 2.0 × ULN (≤ 3.0 × ULN allowed for documented Gilbert syndrome); AST and ALT ≤ 5.0 × ULN.\n* Renal: serum creatinine ≤ 1.5 × ULN, or estimated creatinine clearance (e.g., Cockcroft-Gault) ≥ 40 mL\u002Fmin.\n* Adequate cardiopulmonary reserve to tolerate lymphodepleting conditioning and cell infusion in the investigator's judgment.\n\n  10\\. Viral serology\n* No evidence of uncontrolled active viral infection.\n* HIV-1\u002F2 negative.\n* Hepatitis B: HBV DNA is negative.\n* Hepatitis C: HCV RNA is negative. 11. Contraception\n* Women of childbearing potential and men whose partners are of childbearing potential must agree to use highly effective contraception from the time of informed consent through at least 12 months after BTC-Ag-T infusion (or longer if required by local regulation).\n\n  12\\. Pregnancy status\n* Women of childbearing potential must have a negative serum or urine pregnancy test at screening.\n\n  13\\. Informed consent\n* Able to understand and willing to sign a written informed consent document, and willing to comply with study procedures.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will be excluded:\n\n1. Mixed\u002Fcombined hepatocellular-cholangiocarcinoma, ampullary carcinoma, and other histologies not consistent with BTC\n2. Prior allogeneic transplant or recent gene-modified cell therapy\n3. Active CNS metastases\n4. Patients with uncontrolled or high-risk active infection are excluded, including hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), and active tuberculosis (TB).\n5. Active autoimmune disease requiring systemic immunosuppression\n6. Significant cardiovascular disease\n7. Significant pulmonary disease\n8. Severe hepatic decompensation\n9. Active variceal bleeding, or recent life-threatening portal-hypertension complications that cannot be stably controlled.\n10. Another primary malignancy within the past 3 years, except: tumors treated with curative intent and at low risk of recurrence (e.g., adequately treated basal- or squamous-cell skin cancer, in-situ cervical cancer, or low-Gleason localized prostate cancer, occult thyroid carcinoma).\n11. Severe hypersensitivity.\n12. Pregnant or lactating women\n13. Concurrent participation in another interventional study\n14. Any other condition that, in the investigator's judgment, renders the patient unsuitable for enrollment.",{"count":396,"type":19},18,[398],"PHASE1","BTC-Ag-T (ACH-AgT001) is an autologous experimental T-cell therapy designed for advanced biliary tract cancer. This is an open-label, single-arm Phase 1 study to evaluate the safety, tolerability, and preliminary efficacy of BTC-Ag-T in patients with advanced, unresectable, or metastatic biliary tract cancer who have failed standard-of-care therapy.",[401,402,403,404,405],"Biliary Tract Neoplasms","Cholangiocarcinoma, Intrahepatic","Cholangiocarcinoma, Extrahepatic","Cholangiocarcinoma, Perihilar","Gallbladder Cancer",[407,408,409,410,411,412,413,414,415,163],"Adoptive T-cell therapy","Antigen-specific T cells","CD160","Autologous T cell therapy","Biliary tract cancer","Cholangiocarcinoma","APTC - antigen-presenting tumor cell","Lymphodepletion","Phase 1","2026-05-28",{"date":418,"type":35},"2026-05-29",{"date":420,"type":19},"2026-05",{"date":422,"type":19},"2029-12",{"name":41,"class":42},{"id":425,"slug":4,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":430,"minAge":16,"maxAge":431,"enrollmentInfo":432,"targetDuration":4,"studyType":53,"phases":433,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":443,"leadSponsor":444,"locationsCount":43},"100638490","NCT07616037","Efficacy of a GLP-1\u002FFGF21 Dual Agonist for Treating PCOS","A Preliminary Study to Explore the Efficacy of a GLP-1\u002FFGF21 Dual Agonist (HEC88473) in Patients With Polycystic Ovary Syndrome (PCOS)","Inclusion Criteria:\n\n* Age between 18 and 40 years.\n* Female.\n* No plan for pregnancy from the time of signing the informed consent until 2 months after the last dose of study drug, and willingness to use study-approved contraceptive methods during this period.\n* Fulfillment of at least two of the diagnostic criteria for PCOS according to the 2023 International Guideline, including:\n\n  1. Irregular menstrual cycles:\n\n     1-3 years after menarche: cycle length \\\u003C21 days or \\>45 days; ≥3 years after menarche to perimenopause: cycle length \\\u003C21 days or \\>35 days, or fewer than 8 menstrual cycles per year; ≥1 year after menarche: any cycle \\>90 days;\n  2. Polycystic ovarian morphology: at least one ovary with ≥20 antral follicles (diameter \\\u003C10 mm), confirmed by transvaginal or transrectal pelvic ultrasonography;\n  3. Hyperandrogenism: biochemical hyperandrogenism (total testosterone \\>1.67 nmol\u002FL) or clinical hyperandrogenism (modified Ferriman-Gallwey \\[mFG\\] score \\>4).\n\nExclusion Criteria:\n\n* Use of hormonal contraceptives within 2 months prior to screening.\n* History of acute or chronic pancreatitis or pancreatic injury.\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2A or 2B.\n* History of type 1 or type 2 diabetes mellitus.\n* Presence of other endocrine disorders that may cause polycystic ovarian morphology, such as 21-hydroxylase deficiency, pituitary prolactinoma, hypothyroidism, or Cushing's syndrome.\n* Current use of other medications known to affect reproductive function, with discontinuation less than 2 months prior to screening, including GnRH agonists or antagonists, anti-androgens, and gonadotropins.\n* Current use of other medications that may affect metabolism, with discontinuation less than 1 month prior to screening, including metformin, thiazolidinediones, and SGLT2 inhibitors.\n* History of bariatric surgery within the past 12 months.\n* Treatment with GLP-1 receptor agonists within the past 12 months.\n* Pregnancy or lactation.\n* Presence of other serious diseases of major organs such as the heart, liver, or kidney, or any malignancy.\n* Any other condition that, in the investigator's opinion, may interfere with the evaluation of efficacy or safety or render the participant unsuitable for this study.","FEMALE","40 Years",{"count":290,"type":19},[157],"Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine and metabolic disorder among women of reproductive age. It is characterized by oligo-ovulation or anovulation, clinical and\u002For biochemical hyperandrogenism, and polycystic ovarian morphology. In addition, PCOS is frequently accompanied by multiple metabolic abnormalities, including insulin resistance, obesity, impaired glucose tolerance, and dyslipidemia. Clinical studies have demonstrated that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in women with PCOS results in significant weight reduction, decreased free testosterone levels, improvement in menstrual regularity, and increased clinical pregnancy rates. Fibroblast growth factor 21 (FGF21) has been shown to enhance insulin sensitivity, promote fatty acid oxidation, and improve lipid distribution.\n\nHEC88473 is a novel long-acting dual agonist targeting both the glucagon-like peptide-1 (GLP-1) receptor and the fibroblast growth factor 21 (FGF21) receptor. This study is initiated to evaluate the clinical efficacy of HEC88473 in women with PCOS and to explore its potential as a new therapeutic option for the management of PCOS.",[436],"PCOS (Polycystic Ovary Syndrome)",[438,439],"PCOS","GLP-1\u002FFGF21 dual agonist","2026-05-25",{"date":418,"type":35},{"date":210,"type":19},{"date":168,"type":19},{"name":41,"class":42},{"id":446,"slug":4,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":451,"targetDuration":453,"studyType":20,"phases":4,"briefSummary":454,"conditions":455,"keywords":458,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":326},"100640946","NCT07613996","Impact of Hyperemic State on Angio-IMR Performance","The Impact of Hyperemic State on the Performance of Angiography Derived Indices in Assessing Coronary Microvascular Disease","Inclusion Criteria:\n\n* Stable angina or suspected coronary heart disease.\n* Scheduled for coronary angiography and physiological assessment.\n* Target vessel with stenosis \\\u003C 50% or 50%-90% with fractional flow reserve (FFR) \\> 0.80.\n* Provided informed consent.\n\nExclusion Criteria:\n\n* Hemodynamic instability (acute myocardial infarction, cardiogenic shock, severe arrhythmia).\n* Contraindications to angiography (e.g., end-stage renal disease).\n* Contraindications to adenosine (e.g., severe asthma, high-degree atrial-ventricular block).\n* Life expectancy \\\u003C 1 year or pregnancy.\n* Target vessel unsuitable for wire operation (left main lesion, severe tortuosity) or stenosis \\> 90%.",{"count":452,"type":19},192,"1 Day","The goal of this observational study is to evaluate the diagnostic performance of angiography-derived microcirculatory indices (Angio-IMR) in assessing patients with stable angina or suspected coronary artery disease. The main questions it aims to answer are:\n\nHow do the numerical values of Angio-IMR from five different software vendors change across three physiological states (resting, sub-hyperemia induced by nitroglycerin, and maximal hyperemia induced by adenosine)? Which physiological state and software algorithm provide the highest diagnostic accuracy (Area Under the Curve, AUC) for diagnosing Coronary Microvascular Disease (CMD) when compared to the gold standard wire-based IMR? Researchers will compare the Angio-IMR results calculated under the three different physiological conditions within the same patient to see how the hyperemic state impacts the performance and consistency of these non-invasive indices.\n\nParticipants will:\n\nUndergo standard-of-care coronary angiography and physiological assessment using a pressure wire for index of microvascular resistance (Wire-IMR) as part of their clinical management.\n\nHave their angiographic images captured at three specific time points: at rest, after intracoronary nitroglycerin, and during adenosine-induced maximal hyperemia.\n\nAllow their de-identified imaging and clinical data to be analyzed by an independent core laboratory using five different Angio-IMR software platforms to evaluate microvascular function.",[456,457],"Coronary Artery Disease","Microvascular Coronary Artery Disease",[459,460,461,462],"Coronary Physiology","Computational Fluid Dynamics","Index of Microcirculatory Resistance","Angiography-Derived Indices","2026-05-21",{"date":418,"type":35},{"date":466,"type":35},"2026-05-04",{"date":468,"type":19},"2026-12-31",{"name":41,"class":42},{"id":471,"slug":4,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":53,"phases":478,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":487,"leadSponsor":489,"locationsCount":4},"100608735","NCT07205419","Eye-Tracking Communication Tool for Non-verbal ICU Patients","Co-design and Pilot Feasibility Evaluation of an Eye-tracking Communication Tool for Conscious Non-verbal ICU Patients: Study Protocol for a Feasibility Randomized Controlled Trial","Inclusion Criteria:\n\n* aged ≥ 18 years\n* ICU stay ≥ 24 hours\n* unable to communicate through normal verbal means due to endotracheal intubation\u002Ftracheotomy, muscle or nerve injury, acute\u002Fchronic spinal cord injury, etc.\n* Richmond Agitation-Sedation Scale (RASS) score ranging from -1 to 1\n* able to comply with simple instructions for study participation\n\nExclusion Criteria:\n\n* blindness or inability to elevate the eyelids that preclude successful participation in eye-tracking interaction tasks\n* cognitive impairment limiting meaningful participation\n* severe psychological distress",{"count":477,"type":19},40,[55],"The objectives of this clinical trial are to explore the feasibility of the eye-tracking communication tool in alleviating communication barriers among non-verbal ICU patients. It will also preliminarily investigate the effectiveness of this tool in facilitating communication for these patients.\n\nResearchers will compare the eye-tracking communication tool with conventional techniques (such as body language, writing boards, etc.) to observe the feasibility and preliminary effectiveness of the eye-tracking communication tool in alleviating communication barriers.\n\nParticipants will use an eye-tracking communication tool for augmentative communication for 2 consecutive days.",[481,482,483],"Communication Barriers","Eye-tracking Technology","ICU Patients",{"date":485,"type":35},"2026-05-27",{"date":32,"type":19},{"date":488,"type":19},"2028-06-30",{"name":41,"class":42},{"id":491,"slug":4,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":264,"enrollmentInfo":496,"targetDuration":4,"studyType":53,"phases":498,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":506,"leadSponsor":507,"locationsCount":4},"100638399","NCT07587034","HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer","MATCH-001: A Multicenter, Open-Label, Randomized Controlled Trial of Hepatic Arterial Infusion Chemotherapy Followed by Transarterial Chemoembolization Combined With Apatinib and Camrelizumab in Patients With Intermediate and Advanced Hepatocellular Carcinoma","Inclusion Criteria\n\n1. Age 18-80 years.\n2. Diagnosed with hepatocellular carcinoma (HCC) in accordance with the Standardization for Diagnosis and Treatment of Primary Hepatic Carcinoma (2024 Edition) issued by the National Health Commission of the People's Republic of China.\n3. BCLC stage B or C, with no indication or refusal of surgical treatment, and measurable lesions meeting the mRECIST (Modified Response Evaluation Criteria in Solid Tumors) criteria on baseline imaging.\n4. Child-Pugh liver function grade A or well-compensated grade B (score ≤7).\n5. ECOG Performance Status (PS) score 0-1.\n6. Expected survival time ≥12 weeks.\n\nExclusion Criteria\n\n1. Prior transarterial chemoembolization (TACE) or other local therapies for HCC (except bridging liver transplantation).\n2. Active viral hepatitis (hepatitis B or C) with pre-treatment viral load \\>100 IU\u002FmL (positive for HCV RNA or HBV DNA) or without consistent antiviral therapy.\n3. Alcohol abuse or pregnancy.\n4. Concurrent other malignancies or history of other malignancies within the past 3 years.\n5. Renal dysfunction (creatinine \\[Cr\\] \\>2 mg\u002FdL or creatinine clearance \\[CCr\\] \\\u003C30 mL\u002Fmin) or severe organic diseases of vital organs (heart, lung, brain, etc.).\n6. Inability to cooperate with interventional procedures.\n7. Presence of distant metastasis.\n8. Main portal vein tumor thrombus accompanied by impaired portal venous blood flow and collateral circulation.\n\nWithdrawal Criteria\n\n1. Identification of non-compliance with the study protocol during the trial.\n2. Administration of radiotherapy or other interventions during the trial that prevent efficacy evaluation.\n3. Discontinuation of treatment due to severe adverse reactions (excluded from efficacy analysis but included in adverse reaction statistics).\n4. Patient or representative withdraws informed consent or requests to stop treatment.\n5. Loss to follow-up or death of the patient.\n\nKey Terminology Notes\n\n* National Health Commission of the People's Republic of China: Official English name of the Chinese health authority, consistent with government documentation.\n* Standardization for Diagnosis and Treatment of Primary Hepatic Carcinoma (2024 Edition) : Translated title of the 2024 national guideline for HCC diagnosis and treatment, aligning with the 2022 edition's official English translation published in Cancer Research on Prevention and Treatment.\n* mRECIST: Abbreviation for Modified Response Evaluation Criteria in Solid Tumors, the standard for assessing treatment response in HCC, widely used in clinical trials.\n* BCLC Staging: Barcelona Clinic Liver Cancer staging system, a globally recognized framework for HCC prognosis and treatment decision-making.\n* Child-Pugh Score: A widely used tool to assess liver function in patients with cirrhosis, with grades A (5-6 points), B (7-9 points), and C (10-15 points).\n* ECOG PS Score: Eastern Cooperative Oncology Group Performance Status, a scale from 0 (fully active) to 5 (dead) used to evaluate a patient's ability to perform daily activities.",{"count":497,"type":19},315,[398,157],"To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.",[501],"Liver Cancer","2026-05-16",{"date":504,"type":35},"2026-05-20",{"date":210,"type":19},{"date":422,"type":19},{"name":41,"class":42},{"id":509,"slug":4,"hasResults":11,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":154,"enrollmentInfo":514,"targetDuration":4,"studyType":53,"phases":516,"briefSummary":517,"conditions":518,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":524,"leadSponsor":525,"locationsCount":43},"100640764","NCT07602062","Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis","Multicenter Randomized Controlled Clinical Trial on Direct Oral Novel Anticoagulants for Improving the Prognosis of Cirrhotic Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis","Inclusion Criteria:\n\n* Clinical and imaging diagnosis of liver cirrhosis and esophagogastric varices, with at least one previous episode of esophagogastric variceal bleeding\n* Combined with portal vein thrombosis and D-dimer \\> 0.8mg\u002FL\n* Endoscopic evaluation reveals a high risk of variceal bleeding, and endoscopic treatment is performed to prevent rebleeding of esophagogastric varices\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Received other antithrombotic therapies before (including warfarin, aspirin, low-molecular-weight heparin, etc.)\n* Combined with hepatocellular carcinoma or other malignancy\n* Combined with portal cavernoma\n* Combined with severe life-threatening diseases of circulatory, hematological and respiratory system\n* Combined with diseases requiring anticoagulant therapy, such as acute portal vein thrombosis, atrial fibrillation, lower extremity venous thrombosis, and pulmonary embolism\n* Received TIPS or liver transplantation or splenectomy\n* With contraindications to anticoagulant therapy (uncontrollable active bleeding, severe hepatic insufficiency, renal insufficiency, etc.)\n* Currently taking immunosuppressive agents, or medications that affect cytochrome P450 (including azole antifungals and protease inhibitors), or strong inducers of CYP3A4 (including rifampicin, phenytoin, carbamazepine, etc.)",{"count":515,"type":19},175,[55],"This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis, through a prospective, multicenter, randomized controlled clinical trial, starting 48 hours after endoscopic treatment to prevent rebleeding.",[519,520,521],"Portal Vein Thrombosis","Anticoagulant Therapy","Variceal Bleeding",{"date":367,"type":35},{"date":255,"type":19},{"date":88,"type":19},{"name":41,"class":42},{"id":527,"slug":4,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":534,"conditions":535,"keywords":538,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":546,"locationsCount":43},"100620518","NCT07358663","Treatment Outcomes for Portal Hypertension Esophageal and Gastric Varices","Assessment of Treatment Outcomes for Esophageal and Gastric Varices Secondary to Portal Hypertension","Inclusion Criteria:\n\n* Clinical diagnosis of portal hypertension with esophagogastric varices.\n* Underwent abdominal CT and gastroscopy examinations.\n\nExclusion Criteria:\n\n* Presence of peptic ulcer, gastric tumor, or other causes of gastrointestinal bleeding confirmed by imaging or gastroscopy.\n* CT images of inadequate quality or incomplete medical history data.",{"count":533,"type":19},1384,"This study is a single-center, prospective cohort study based on real-world data. Patients with portal hypertension and esophagogastric varices were enrolled and divided into an endoscopic treatment group and a non-endoscopic treatment group (including patients receiving medical therapy, interventional procedures, or surgical treatment) according to whether they underwent endoscopic intervention. Baseline data, serum metabolites, CT imaging and endoscopic images, liver biopsy pathology, and other multi-omics data were integrated for both groups. Patients were followed up to compare adverse events after variceal treatment, including rebleeding and its causes, hepatic encephalopathy, ascites, subsequent treatments (such as regular endoscopic therapy, NSSB, and TIPS), and survival outcomes. Clinical characteristics of portal hypertension attributed to different etiologies, including hepatitis B, autoimmune liver disease, schistosomiasis, hematological disorders, and chemotherapy-induced liver injury, were compared. The efficacy and safety of endoscopic and interventional treatments for esophagogastric varices were evaluated. Factors influencing rebleeding rates among different treatment groups were analyzed, and reasons for inclusion in different groups were discussed.",[536,537],"Esophagogastric Varices","Portal Hypertension",[539,540],"endoscopic treatment","portal hypertension","2026-05-12",{"date":279,"type":35},{"date":544,"type":35},"2026-01-20",{"date":145,"type":19},{"name":41,"class":42},{"id":548,"slug":4,"hasResults":11,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":154,"enrollmentInfo":553,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":563,"locationsCount":4},"100638838","NCT07577544","Pulsed Field Ablation in the Coronary Sinus: Feasibility and Safety of a Novel Approach for Mitral Isthmus Block","Safety, Efficacy and Mid-term Outcomes of Pulsed Field Ablation for Mitral Isthmus Ablation Through Epicardial Approach","Inclusion Criteria:\n\n* Symptomatic Atrial Fibrillation: participants must have a diagnosis of symptomatic paroxysmal or persistent atrial fibrillation.\n* Documentation: The arrhythmia must be documented by electrocardiogram or Holter monitoring.\n* Age Range: participants must be between 18 and 75 years of age.\n* Study Compliance: participants must be willing and able to comply with the post-procedural follow-up schedule.\n* Procedural Requirement: All patients must be candidates for linear ablation at the mitral isthmus (MI) and coronary sinus (CS) for substrate modification.\n\nExclusion Criteria:\n\n* Prior Cardiac Procedures: Patients with a history of prior heart surgery or Left Atrial Appendage Occlusion (LAAO) are excluded.\n* Heart Failure Severity: Individuals classified with New York Heart Association (NYHA) functional class III or IV are ineligible.\n* Renal Impairment: Patients with advanced renal failure, defined as an estimated glomerular filtration rate (eGFR) below 30 mL\u002Fmin\u002F1.73m², are excluded.\n* Intracardiac Thrombus: Any patient with a left atrial thrombus identified via transesophageal echocardiography (TEE) is excluded.",{"count":290,"type":19},"Why This Study Is Important\n\n* Many patients with atrial fibrillation (AF) continue to experience abnormal heart rhythms even after receiving standard treatments.\n* Standard heat-based energy can be difficult to use in these areas because fast blood flow cools the tissue, and excessive heat may damage nearby structures like the right coronary artery.\n\nOur Approach\n\n* Investigators are testing a newer technology called pulsed field ablation (PFA).\n* Unlike traditional methods, PFA uses ultra-short electrical pulses rather than heat to target heart cells specifically while protecting neighboring nerves and blood vessels.\n* This study focuses on applying this energy within the coronary sinus to help achieve a more complete and lasting electrical block for the mitral isthmus.\n\nWhat To Expect\n\n* This study involves 30 participants who are already undergoing a catheter ablation procedure for atrial fibrillation.\n* The research team will monitor how successful the procedure is at immediately stopping the abnormal electrical signals.\n* Participants will have follow-up visits over six months to check for any returning heart rhythm issues and will receive a specialized heart scan (CTA) to ensure the nearby coronary arteries remain healthy",[556],"Atrial Fibrillation (AF)","2026-05-09",{"date":559,"type":35},"2026-05-13",{"date":561,"type":19},"2026-05-15",{"date":110,"type":19},{"name":41,"class":42},{"id":565,"slug":4,"hasResults":11,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":264,"enrollmentInfo":569,"targetDuration":4,"studyType":53,"phases":571,"briefSummary":572,"conditions":573,"keywords":579,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":43},"100577113","NCT06794073","Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender.\n2. Clinically or pathologically confirmed HCC.\n3. CNLC stage IIb-IIIa, deemed unresectable after multidisciplinary evaluation.\n4. Having radiologically evaluable, untreated target lesions for ablation, with the largest diameter of the target tumor \\>5 cm.\n5. Patients who have not undergone systemic chemotherapy, targeted therapy, or immunotherapy for hepatocellular carcinoma, or those who have been evaluated as SD (stable disease) or PD (progressive disease) after treatment..\n6. ECOG PS 0-1 and an expected survival \\>3 months.\n7. Child-Pugh score ≤7.\n\nExclusion Criteria:\n\n1. Child-Pugh class C liver dysfunction.\n2. Tumor thrombus in the main portal vein or hepatic vein.\n3. Extensive metastatic disease with an expected survival \\\u003C3 months.\n4. Severe dysfunction of major organs (liver, kidney, heart, lung, or brain).\n5. History of esophageal\u002Fgastric variceal bleeding within the past month.\n6. History of other malignancies.\n7. Last anti-tumor therapy (e.g., radiotherapy, systemic chemotherapy, or local treatment) within \\\u003C1 month.\n8. Active infection; HBV co-infection (HBV DNA ≥2000 IU\u002FmL or ≥10⁴ copies\u002FmL unless reduced by one log after antiviral therapy); HCV co-infection requiring guideline-directed antiviral treatment; HIV infection; or biliary tract inflammation.\n9. History of organ transplantation or hepatic encephalopathy.\n10. Uncorrectable coagulation disorders.\n11. Refractory massive ascites, pleural effusion, or cachexia.\n12. Pregnancy, impaired consciousness, or inability to comply with treatment.\n13. High tumor burden (sum of the largest liver lesion diameter and number of liver lesions \\>12).\n14. Any other condition deemed unsuitable by investigators that may affect study participation.",{"count":570,"type":19},17,[55],"This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, Tislelizumab, and lenvatinib in the treatment of unresectable primary liver cancer.",[574,575,576,577,578],"Carcinoma, Hepatocellular","Neoplasms, Glandular and Epithelial","Adenocarcinoma","Digestive System Neoplasms","Liver Neoplasms",[580,581,582,583,584],"Multimodal","Tislelizumab","lenvatinib","TACE","unresectable primary liver cancer","2026-05-08",{"date":143,"type":35},{"date":588,"type":35},"2026-01-31",{"date":590,"type":19},"2027-08-31",{"name":41,"class":42},""]